Vindesine in the treatment of malignant mesothelioma: A phase II study

D. Kelsen, Richard J. Gralla, E. Cheng, N. Martini

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m2 was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95% confidence limits, 0%-17%). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.

Original languageEnglish (US)
Pages (from-to)821-822
Number of pages2
JournalCancer Treatment Reports
Volume67
Issue number9
StatePublished - 1983
Externally publishedYes

Fingerprint

Vindesine
Vinca Alkaloids
Poisons
Alopecia
Leukopenia
Peripheral Nervous System Diseases
Therapeutics
Malignant Mesothelioma
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kelsen, D., Gralla, R. J., Cheng, E., & Martini, N. (1983). Vindesine in the treatment of malignant mesothelioma: A phase II study. Cancer Treatment Reports, 67(9), 821-822.

Vindesine in the treatment of malignant mesothelioma : A phase II study. / Kelsen, D.; Gralla, Richard J.; Cheng, E.; Martini, N.

In: Cancer Treatment Reports, Vol. 67, No. 9, 1983, p. 821-822.

Research output: Contribution to journalArticle

Kelsen, D, Gralla, RJ, Cheng, E & Martini, N 1983, 'Vindesine in the treatment of malignant mesothelioma: A phase II study', Cancer Treatment Reports, vol. 67, no. 9, pp. 821-822.
Kelsen D, Gralla RJ, Cheng E, Martini N. Vindesine in the treatment of malignant mesothelioma: A phase II study. Cancer Treatment Reports. 1983;67(9):821-822.
Kelsen, D. ; Gralla, Richard J. ; Cheng, E. ; Martini, N. / Vindesine in the treatment of malignant mesothelioma : A phase II study. In: Cancer Treatment Reports. 1983 ; Vol. 67, No. 9. pp. 821-822.
@article{886e5022263746fc9e68ec2e403d1d69,
title = "Vindesine in the treatment of malignant mesothelioma: A phase II study",
abstract = "Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m2 was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95{\%} confidence limits, 0{\%}-17{\%}). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.",
author = "D. Kelsen and Gralla, {Richard J.} and E. Cheng and N. Martini",
year = "1983",
language = "English (US)",
volume = "67",
pages = "821--822",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Vindesine in the treatment of malignant mesothelioma

T2 - A phase II study

AU - Kelsen, D.

AU - Gralla, Richard J.

AU - Cheng, E.

AU - Martini, N.

PY - 1983

Y1 - 1983

N2 - Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m2 was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95% confidence limits, 0%-17%). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.

AB - Vindesine (VDS) is a new semisynthetic vinca alkaloid which has demonstrated therapeutic activity against a variety of solid tumors. A phase II trial of this agent was performed in patients with advanced malignant mesothelioma. VDS at a dose of 3 mg/m2 was given iv once weekly for 4-6 weeks and then every 2 weeks thereafter. Only one of 17 evaluable patients had a partial remission, lasting 5 months (95% confidence limits, 0%-17%). Toxic effects of VDS included leukopenia, peripheral neuropathy, and alopecia. VDS has minimal activity in malignant mesothelioma.

UR - http://www.scopus.com/inward/record.url?scp=0020589022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020589022&partnerID=8YFLogxK

M3 - Article

C2 - 6883358

AN - SCOPUS:0020589022

VL - 67

SP - 821

EP - 822

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -